Literature DB >> 29029108

Relative Risks of Contributing Factors to Morbidity and Mortality in Adults With Craniopharyngioma on Growth Hormone Replacement.

Kevin C J Yuen1, Anders F Mattsson2, Pia Burman3, Eva-Marie Erfurth3, Cecilia Camacho-Hubner4, Janet L Fox4, Johan Verhelst5, Mitchell E Geffner6, Roger Abs7.   

Abstract

Context: In adults, craniopharyngioma (CP) of either childhood-onset (CO-CP) or adult-onset (AO-CP) is associated with increased morbidity and mortality, but data on the relative risks (RRs) of contributing factors are lacking. Objective: To assess the RRs of factors contributing to morbidity and mortality in adults with CO-CP and AO-CP.
Methods: Data on 1669 patients with CP from KIMS (Pfizer International Metabolic Database) were analyzed using univariate and multiple Poisson and Cox regression methods.
Results: When CO-CP and AO-CP groups were combined, history of stroke and hyperlipidemia increased cardiovascular risk, higher body mass index (BMI) and radiotherapy increased cerebrovascular risk, and increased waist circumference increased the risk of developing diabetes mellitus (DM). Compared with patients with CO-CP, patients with AO-CP had a threefold higher risk of tumor recurrence, whereas being female and previous radiotherapy exposure conferred lower risks. Radiotherapy and older age with every 10 years from disease onset conferred a 2.3- to 3.5-fold risk for developing new intracranial tumors, whereas older age, greater and/or increasing BMI, history of stroke, and lower insulinlike growth factor I (IGF-I) standard deviation score measured at last sampling before death were related to increased all-cause mortality. Compared with the general population, adults with CP had 9.3-, 8.1-, and 2.2-fold risks of developing DM, new intracranial tumors, and early death, respectively.
Conclusion: Conventional factors that increase the risks of cardio- and cerebrovascular diseases and DM and risks for developing new intracranial tumors contributed to excess morbidity and mortality. In addition, lower serum IGF-I level measured from the last sample before death was inversely associated with mortality risk in patients with CP.
Copyright © 2017 Endocrine Society

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29029108     DOI: 10.1210/jc.2017-01542

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

Review 1.  Excess mortality after craniopharyngioma treatment: are we making progress?

Authors:  Nidan Qiao
Journal:  Endocrine       Date:  2018-12-19       Impact factor: 3.633

2.  Vasculometabolic effects in patients with congenital growth hormone deficiency with and without GH replacement therapy during adulthood.

Authors:  Isabela Peixoto Biscotto; Valéria Aparecida Costa Hong; Rafael Loch Batista; Berenice Bilharinho Mendonca; Ivo Jorge Prado Arnhold; Luiz Aparecido Bortolotto; Luciani Renata Silveira Carvalho
Journal:  Pituitary       Date:  2020-10-24       Impact factor: 4.107

Review 3.  Management of Hypopituitarism.

Authors:  Krystallenia I Alexandraki; AshleyB Grossman
Journal:  J Clin Med       Date:  2019-12-05       Impact factor: 4.241

Review 4.  Endocrine Disorder in Patients With Craniopharyngioma.

Authors:  Zihao Zhou; Sheng Zhang; Fangqi Hu
Journal:  Front Neurol       Date:  2021-12-02       Impact factor: 4.003

5.  Raised cardiovascular disease mortality after central nervous system tumor diagnosis: analysis of 171,926 patients from UK and USA.

Authors:  Kai Jin; Paul M Brennan; Michael T C Poon; Cathie L M Sudlow; Jonine D Figueroa
Journal:  Neurooncol Adv       Date:  2021-09-21

Review 6.  Safety of growth hormone (GH) treatment in GH deficient children and adults treated for cancer and non-malignant intracranial tumors-a review of research and clinical practice.

Authors:  Margaret C S Boguszewski; Adriane A Cardoso-Demartini; Cesar Luiz Boguszewski; Wassim Chemaitilly; Claire E Higham; Gudmundur Johannsson; Kevin C J Yuen
Journal:  Pituitary       Date:  2021-07-25       Impact factor: 4.107

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.